Biogen Inc. (BIIB)

268.03
NASDAQ : Health Technology
Prev Close 268.03
Day Low/High 0.00 / 0.00
52 Wk Low/High 244.28 / 370.57
Avg Volume 1.69M
Exchange NASDAQ
Shares Outstanding 211.56M
Market Cap 55.66B
EPS 11.90
P/E Ratio 22.21
Div & Yield N.A. (N.A)

Latest News

Biogen And Samsung Bioepis Agree To Settlement With AbbVie Allowing Commercialization Of IMRALDI™ (Adalimumab Biosimilar) In Europe

Biogen And Samsung Bioepis Agree To Settlement With AbbVie Allowing Commercialization Of IMRALDI™ (Adalimumab Biosimilar) In Europe

Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® (adalimumab).

Biogen To Report First Quarter 2018 Financial Results On April 24, 2018

Biogen To Report First Quarter 2018 Financial Results On April 24, 2018

Biogen Inc. (NASDAQ:BIIB) today announced it will report first quarter 2018 financial results on Tuesday, April 24, 2018, before the financial markets open.

Biogen Is In a Downtrend With Further Risk Ahead

Biogen Is In a Downtrend With Further Risk Ahead

Charts are signalling more trouble ahead for the stock.

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.

Biogen To Present At The 2018 Advances In Alzheimer's And Parkinson's Therapies (AAT-AD/PD) Focus Meeting

Biogen To Present At The 2018 Advances In Alzheimer's And Parkinson's Therapies (AAT-AD/PD) Focus Meeting

Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting in...

Biogen To Present At The Advances In Alzheimer's And Parkinson's Therapies, An AAT-AD/PD Focus Meeting

Biogen To Present At The Advances In Alzheimer's And Parkinson's Therapies, An AAT-AD/PD Focus Meeting

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Advances in Alzheimer's and Parkinson's Therapies, an AAT-AD/PD Focus Meeting.

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...

Biogen To Acquire From Pfizer First-in-Class Phase 2b Ready Asset For Cognitive Impairment Associated With Schizophrenia

Biogen To Acquire From Pfizer First-in-Class Phase 2b Ready Asset For Cognitive Impairment Associated With Schizophrenia

Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc.

Tempur Sealy Is Lying Down, Plus 4 Other Stocks That Look Good Short

TPX, WR, GOV, BIIB and SRE were all recently were downgraded by TheStreet's Quant Ratings service.

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.

Biogen To Present At The Cowen And Company 38th Annual Health Care Conference

Biogen To Present At The Cowen And Company 38th Annual Health Care Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen and Company 38 th Annual Health Care Conference.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AC, BJRI, SUN, UNT Downgrades: AAC, BELFA, BIIB, BMCH, EIX, GXP, KMX, LAWS, LUK, MUX, RPXC, TPX, VDSI, WR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

Biogen (Nasdaq: BIIB) announced today that in the Phase 2b dose-ranging ACTION 2 study in individuals with acute ischemic stroke (AIS), natalizumab did not demonstrate improvement in clinical outcomes compared to placebo.

Biogen To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Biogen To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 7th Annual Global Healthcare Conference.

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

The challenge of this market is to keep finding new buy entries as more and more stocks become extended.

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Here's what you need to know now for Thursday, Jan. 25

Dow and S&P 500 Jump to New Records as Nasdaq Slips

Dow and S&P 500 Jump to New Records as Nasdaq Slips

The Dow soared 140 points on Thursday.

Stocks Lose Steam, Dow Holds Gains as Caterpillar Turns Lower

Stocks Lose Steam, Dow Holds Gains as Caterpillar Turns Lower

Stocks come off early highs after Caterpillar shares trade lower.

Davos, Caterpillar, Intel, Ford and Kroger - 5 Things You Must Know

Davos, Caterpillar, Intel, Ford and Kroger - 5 Things You Must Know

U.S. stock futures rise as the dollar plunges to a fresh three-year low. Caterpillar, Intel and 3M leading the earnings calendar.

Biogen Reports Record Revenues For Both The Full Year And Fourth Quarter Of 2017, $12.3 Billion And $3.3 Billion, Respectively

Biogen Reports Record Revenues For Both The Full Year And Fourth Quarter Of 2017, $12.3 Billion And $3.3 Billion, Respectively

Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including: Full year total revenues of $12.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

TheStreet Quant Rating: C (Hold)